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The eﬀects of cloﬁbrate on the hemodynamic and renal manifestations of increased saline intake were analyzed. Four groups of
male Wistar rats were treated for ﬁve weeks: control, cloﬁbrate (240mg/kg/day), salt (2% via drinking water), and salt+cloﬁbrate.
Body weight, systolic blood pressure (SBP), and heart rate (HR) were recorded weekly. Finally, SBP, HR, and morphologic,
metabolic, plasma, and renal variables were measured. Salt increased SBP, HR, urinary isoprostanes, NOx, ET, vasopressin and
proteinuria and reduced plasma free T4 (FT4) and tissue FT4 and FT3 versus control rats. Cloﬁbrate prevented the increase in
SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels.
However,cloﬁbratedidnotmodifytherelativecardiacmass,NOx,urinaryET,andvasopressinofsaline-loadedrats.Inconclusion,
chronic cloﬁbrate administration prevented the blood pressure elevation of salt-loaded rats by decreasing sodium balance and
reducing thyroid hormone levels.
1.Introduction
Fibrates are synthetic agonists of peroxisome proliferator-
activated receptor-α (PPARα), a subfamily of the nuclear
receptor superfamily naturally activated by ligands such as
free fatty acids and eicosanoids [1]. PPARα is expressed
in the liver and in tissues with highly active fatty acid
metabolism, such as the heart, kidney, endothelium, and
vascular smooth muscle, all primarily related to blood
pressure (BP) control. Fibrates have been in clinical use
as hypolipidemic agents for several decades. More recently,
they have been reported to have beneﬁcial eﬀects on
cardiovascularfunction[1–3]andelevatedBP[4,5].Fibrates
also exert antithyroid eﬀects. PPAR agonists interact with
thyroid receptors (TRs) in part by sharing binding sites
and heterodimeric partners such as RXRs [6–8]. PPARs and
TRs also share coactivators. In addition, the activation of
response elements by TRs and PPARs is modulated by PPAR
agonists [8]. The molecular mechanisms of the negative
interaction between thyroid hormone and PPARs include an
increase in thyroid hormone deactivation [9] and reductions
in the gene expression of their transporters [10–12] and in
the activity of deiodinases [10]a n da c t i o n[ 6, 8, 10–12].
Thus, cloﬁbrate treatment markedly reduced plasma thyroid
hormone levels and increased tissue activity of phenol-UGT,
an enzyme that deactivates thyroid hormones in chronically
t r e a t e dh y p e r t h y r o i dr a t s[ 13].
Theantihypertensiveeﬀectsofcloﬁbrate-inducedPPARα
activation may include the following: higher production of
endothelial [14] and renal [15] nitric oxide, which plays an
important homeostatic role in the response to an increased
saline intake [16]; lower production of reactive oxygen
species and reduced NAD(P)H oxidase activity [3], which
are increased in saline drinking rats [17]; lower production
of ET-1 [3] also elevated in saline models of experimental
hypertension [3, 18]. Moreover, the mechanism responsible
for the protective eﬀects of cloﬁbrate on the development of
hypertension may also be linked to its antithyroid actions,2 Journal of Biomedicine and Biotechnology
since antithyroid drugs have prevented BP elevation in all
experimental rat models of hypertension studied to date
[19]. In this regard, we recently reported [13] that chronic
cloﬁbrate treatment prevented and reversed the characteris-
tic hemodynamic manifestations, increased temperature of
hyperthyroidism in rats, and reduced their plasma thyroid
hormone levels.
All of the above data indicate that PPARα activation can
have important protective eﬀects on cardiovascular function
and interfere with the prohypertensive eﬀects of increased
saline intake, but the precise mechanisms involved have not
beenelucidated.Inthisstudy,weanalyzedtheputativeroleof
several factors, focusing the investigation on the antithyroid
eﬀects of cloﬁbrate.
2. Methods
2.1. Animals. Thirty-two male Wistar rats born and raised in
the experimental animal service of the University of Granada
were used. The experiment was performed according to
European Union guidelines for the ethical care of animals.
Rats initially weighing 280 ± 4g were randomly assigned
to the diﬀerent groups. Each experimental group comprised
eight animals. All rats had free access to food and tap water.
Cloﬁbrate (240mg/kg/day) was given by gavage because of
the low solubility of this compound. The dose of cloﬁbrate
was in accordance with previously published protocols used
in experimental hypertension in rats [3, 13].
2.2. Experimental Protocol. The groups were: control,
cloﬁbrate-treated, salt-loaded (2% NaCl viadrinking water),
and cloﬁbrate plus salt-treated rats. Treatments were admin-
istered for ﬁve weeks. Body weight (BW), tail systolic BP
(SBP), and heart rate (HR) were measured once a week.
Tail SBP and HR were measured with the use of tail-cuﬀ
plethysmography in unanesthetized rats (LE 5001-Pressure
Meter, Letica SA, Barcelona, Spain).
When the experimental period was completed, all rats
were then housed in metabolic cages (Panlab, Barcelona,
Spain) with free access to food and water for a four-day
period (two days for adaptation + two experimental days),
during which food and water intakes were measured, and
urine samples were collected. Twenty-four-hour urine vol-
ume, proteinuria, creatinine, isoprostanes, nitrate-nitrites,
endothelin (ET), vasopressin (VP), and total sodium, potas-
sium, and calcium excretion were measured. Mean values
of all intake and urinary variables obtained during the two
experimental days were used for statistical analyses among
groups.
After completion of the metabolic study, the rats were
anesthetized with ethyl ether. A polyethylene catheter (PE-
50) containing 100 units of heparin in isotonic sterile
NaCl solution was inserted into the femoral artery to
measure intra-arterial BP and HR and pulse pressure (PP) in
consciousratsandtoextractbloodsamples.Intra-arterialBP
was measured at 24h after implantation of femoral catheter.
Direct BP and HR were recorded continuously for 60min
withasamplingfrequencyof400/s(McLab,ADInstruments,
Hastings, UK); BP and HR values obtained during the last
30min were averaged for intergroup comparisons. Subse-
quently, blood samples taken with the femoral catheter were
used to determine plasma variables. The plasma variables
measured were: urea, creatinine, total proteins, electrolytes
(sodium and potassium), thyroid hormones (FT3 and FT4),
and thyroid stimulating hormone (TSH).
Finally, the rats were killed by exsanguination, and the
thyroid, liver, kidneys, and ventricles were removed and
weighed. The heart was divided into right ventricle and
left ventricle plus septum and the kidney was dissected to
separate cortex and medulla. Tissue FT3 and FT4 levels were
measured in liver and renal cortex and medulla.
2.3. Analytical Procedures. Proteinuria was measured by the
m e t h o do fB r a d f o r d[ 20]. Plasma and urinary electrolytes
and creatinine were measured in an autoanalyzer (Hitachi-
912, Roche, Spain). Plasma and tissue levels of thyroid
hormones (free circulating T3 and T4) were determined
using rat radioimmunoassay kits according to the man-
ufacturer’s instructions (Diagnostic Products Corporation,
Los Angeles, CA, USA). An enzyme immunoassay kit (8-
isoprostane EIA Kit, Cayman Ann Arbor, MI, USA) was
used to measure urinary 8-isoprostane levels, and samples
were previously puriﬁed using the Aﬃnity puriﬁcation kit
(Cayman). Immunoreactive urinary ET and VP levels were
measured with a radioimmunoassay kit purchased from
Assay designs, (Ann Arbor, MI, USA). Urine NO
−
2 and
NO
−
3 (NOx) concentrations were measured using nitrate
reductase and Griess reaction [21]. Rat plasma TSH was
measured by a solid phase competitive chemiluminiscent
enzyme immunoassay using the IMMULITE 2000 Analyzer
(EURO/DPC, Llanberis, Gwynedd, UK).
2.4. Preparation of the Tissue Homogenates. For thyroid hor-
mone measurements, the liver and the dissected renal cortex
and medulla were homogenized with a glass homogenizer
in ice-cold HEPES buﬀer containing (mmol/L) sodium
HEPES 25, EDTA 1, phenylmethylsulfonyl ﬂuoride 0.1, and
PBS. After centrifugation of the homogenate at 6000g for
5min at 4 ◦C, the supernatant containing membrane and
cytosolic components, termed homogenate, was separated
into aliquots, frozen in liquid N2,a n ds t o r e da t−80
◦C until
use.
2.5. Statistical Analysis. One-way ANOVA was used to
compare each variable at the end of the experiment. When
the overall ANOVA was signiﬁcant, pairwise comparisons
were performed using Bonferroni’s methods. P<. 05 was
considered signiﬁcant.
3. Results
3.1. Blood Pressure and Heart Rate. BP and HR values are
summarized in Figure 1. The left-hand graph in Figure 1
shows the ﬁnal SBP and the right-hand graph shows the
ﬁnal HR measured by direct recording in the experimental
groups. Saline loading produced an increase in SBP andJournal of Biomedicine and Biotechnology 3
HR and PP in comparison to control rats. Cloﬁbrate
administration to normal rats at the dose and time used in
this experiment produced a modest but signiﬁcant decrease
in BP (4.8 ± 0.6mmHg) and HR (16 ± 5.7beats/min).
Cloﬁbrate administration to saline-loaded rats reduced SBP,
HR (14 ± 0.7mmHg and 50 ± 5.7beats/min, respectively,
∗P<. 01 versus saline-drinking rats for both variables), and
PP values. Hence, the salt+cloﬁbrate group showed similar
ﬁnal SBP, HR, and PP values to those of control rats. PP
values in the groups were: control, 36.2 ± 1.2; cloﬁbrate,
31.2±2.2; salt, 45.3±1.2
∗; salt+cloﬁbrate, 37.3±1.5+ (∗P<
.01 versus controls; +P<. 01 versus saline group).
3.2. Morphological Variables. Body weight at the end of the
ﬁve-week study period was signiﬁcantly lower in the salt
and cloﬁbrate+salt groups than in controls. Absolute kidney
weight was signiﬁcantly increased and the absolute left
ventricular weight was reduced in the salt+cloﬁbrate group.
Kidney-to-body weight ratio was signiﬁcantly increased in
the cloﬁbrate and salt groups and was markedly increased
in the cloﬁbrate+salt group. Left ventricular-to-body weight
and left ventricular-to-right ventricular ratios, both indexes
of cardiac hypertrophy, were not signiﬁcantly modiﬁed by
the treatments. The thyroid weight-to-body weight ratio
was not signiﬁcantly modiﬁed in the groups. The liver-to-
body weight ratio was signiﬁcantly increased in the cloﬁbrate
group but showed only a nonsigniﬁcant increase in the
salt+cloﬁbrate group (Table 1).
3.3. Plasma Variables and Thyroid Hormone Levels. Plasma
sodiumandpotassiumlevelsweresimilaramongthecontrol,
cloﬁbrate, and salt groups, but plasma sodium was higher
and potassium lower in the cloﬁbrate+salt group. Plasma
urea and creatinine were similar in all groups, and plasma
protein, an index of plasma volume, was also similar in all
groups (Table 2).
FT3 values were signiﬁcantly decreased in the cloﬁ-
brate+salt group but did not diﬀer among the other groups.
However, FT4 levels were signiﬁcantly reduced in the cloﬁ-
brate and salt groups, especially in the salt+cloﬁbrate group.
TSH values were increased and decreased in the cloﬁbrate
and salt groups, respectively, and were not signiﬁcantly
modiﬁed in the salt+cloﬁbrate group (Table 2).
3.3.1. Metabolic and Urinary Variables. Metabolic studies
at the end of treatment showed increased food and ﬂuid
intake (g/100g body weight) in the salt-treated group in
comparisonwithcontrols.Cloﬁbratetreatmentdidnotaﬀect
food and ﬂuid intake in normal rats but reduced the food
intake in saline-loaded rats (Table 3). Water and sodium
balances were increased in the salt group. Cloﬁbrate reduced
water and sodium balances in saline-loaded rats (Table 3).
Table 4 lists the results for the urinary variables. The
salt group showed increased diuresis, natriuresis, kaliuresis,
and calciuresis. Cloﬁbrate did not signiﬁcantly modify
these variables in control rats but increased the diuresis,
natriuresis, and kaliuresis and reduced the calciuresis in
saline-loaded rats. Total creatinine excretion and creatinine
clearance were similar in all groups.
Proteinuriawasincreasedinthesaltgroup,andcloﬁbrate
reduced this variable in control and saline-drinking rats.
Total isoprostane and NOx excretion were increased in the
salt group, and cloﬁbrate did not signiﬁcantly modify these
variablesincontrolorsalt-loadedrats.Totalimmunoreactive
ET and VP excretion were increased in the salt group, and
cloﬁbrate did not modify these variables in control and salt-
loaded rats.
3.4. Tissue Thyroid Hormone Levels. These results are sum-
marized in Figure 2.E x c e p tf o rF T 3 in the cloﬁbrate group,
FT4 and FT3 values were signiﬁcantly reduced in the liver in
all experimental groups with respect to controls, observing
the greatest reduction in the salt+cloﬁbrate group. In the
renalcortex,asigniﬁcantreductioninFT4 wasonlyobserved
in the salt+cloﬁbrate group, while FT3 was decreased in all
groups, especially in the salt+cloﬁbrate group. In the renal
medulla, FT4 and FT3 were reduced in the salt-loaded group
and more markedly reduced in the salt+cloﬁbrate group.
The salt+cloﬁbrate and salt groups signiﬁcantly diﬀered in
FT4 and FT3 values in all tissues.
4. Discussion
The main ﬁndings of this study were that chronic cloﬁbrate
administration to salt-loaded rats prevented the BP increase
in these animals and that this eﬀect may be mediated by the
antithyroid action of ﬁbrates. Cloﬁbrate treatment markedly
reduced plasma and tissue thyroid hormone levels in saline-
treated rats. These ﬁndings are in agreement with previous
observations by our group in hyperthyroid rats [13]. A
ﬁbrate-induced reduction in thyroid hormone levels may be
protective against hypertension in saline-loaded rats, since
antithyroid drugs are known to prevent the development
of hypertension in rats [19]. We also found that cloﬁbrate
reduced the water and sodium balance in saline-loaded
rats with respect to saline-drinking rats, which may also
contribute to its antihypertensive eﬀect. However, cloﬁbrate
did not signiﬁcantly change nitrite/nitrate, isoprostane, ET,
or VP levels, suggesting that these variables do not play a role
in the prevention of saline load hypertension induced by this
agent.
AnincreaseinBPinresponsetodietarysodium(saltsen-
sitivity)isconsideredanimportantfactorinthepathogenesis
ofhypertensioninhumans[22].Inthepresentstudy,chronic
2%NaClloadingviadrinkingwaterproducedamoderateBP
increase (15mmHg) in male Wistar rats, in agreement with
several reports in Sprague-Dawley rats [3, 18–24]. However,
other studies found no signiﬁcant change in BP with salt
loading in Sprague-Dawley rats [25, 26]. These discrepancies
may reﬂect diﬀerences in the duration of saline loading or in
the administration route (with food or ﬂuid intake).
The antihypertensive eﬀect of cloﬁbrate in the saline-
loaded rats is consistent with previous reports of the
attenuation by ﬁbrates of BP elevation in genetic models of
hypertension [5] and in nitric oxide-deﬁcient and DOCA
salt-treated hypertensive mice and rats [3].
Inthisstudy,cloﬁbrateproducedamodestbutsigniﬁcant
BP reduction in untreated rats, which was also associated4 Journal of Biomedicine and Biotechnology
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Figure 1: Final systolic blood pressure (SBP) and heart rate (HR) measured by direct recording (femoral artery) in conscious rats at the end
of the experimental period (ﬁve weeks). Data are means ± SEM. ∗P<. 05; ∗∗P<. 01 compared with controls; +P<. 01 compared with the
salt group.
Table 1: Morphologic variables in the experimental groups.
Groups Control Cloﬁbrate Salt Salt+cloﬁbrate
FBW, g 381 ±9 368 ±7 325 ±5∗ +284 ±4∗
KW, g 1.19 ±0.03 1.22 ±0.03 1.26 ±0.06 1.33 ±0.02
∗
LVW, g 0.75 ±0.03 0.72 ±0.03 0.69 ±0.02 0.60 ±0.03
∗
KW/BW, mg/g 2.93 ±0.03 3.31 ±0.09
∗ 3.92 ± 0.24
∗ ++5.04 ±0.22
∗∗
LVW/BW, mg/g 1.98 ±0.06 1.98 ±0.05 2.13 ±0.11 2.30 ±0.11
LVW/RVW 3.71 ±0.41 4.24 ±0.52 4.66 ±0.79 3.44 ±0.55
LiW/BW, mg/g 29.97 ±0.75 37.52 ±1.01
∗ 30.86 ±1.39 33.34 ±1.58
TW/BW, mg/g 1.82 ±0.07 2.05 ±0.14 1.60 ±0.09 1.69 ±0.06
Data expressed as means±s.e.m. FBW, ﬁnal body weight; KW, kidney weight; LVW, left ventricular weight; KW/BW, kidney weight versus body weight ratio;
LVW/BW,leftventricularweightversusbodyweightratio;LVW/RVW,leftventricularweightversusrightventricularweightratio;LiW/BW,liverweightversus
body weight ratio; TW/BW, thyroid weight versus body weight ratio. ∗P<. 05, ∗∗P<. 01 versus the control group; +P<. 05, ++P<. 01 versus the salt group.
Table 2: Plasma variables in the experimental groups.
Groups Control Cloﬁbrate Salt Salt+cloﬁbrate
Na, mEq/L 143.00 ±0.87 141.43 ±0.69 144.83 ±1.62 +155.00 ±3.72
∗
K, mEq/L 4.23 ±0.08 4.43 ±0.10 4.12 ±0.19 +3.35 ±0.18
∗
Urea, mg/dL 44.29 ±1.54 49.54 ±2.00 54.05 ±9.34 47.92 ±3.05
Creatinine, mg/dL 0.54 ±0.02 0.51 ±0.01 0.44 ±0.04 0.53 ±0.02
Total Proteins, g/dL 6.12 ±0.08 5.81 ±0.11 5.80 ±0.24 5.81 ±0.44
FT3,p g / m L 2 .78 ±0.08 2.73 ±0.06 2.85 ±0.17 +2.06 ±0.13
∗
FT4, ng/dL 3.23 ±0.16 1.67 ±0.11
∗ 2.22 ±0.19
∗ ++1.29 ±0.21
∗
TSH, ng/dL 3.20 ±0.30 4.10 ±0.12
∗ 2.1 ±0.10
∗ 3.7 ±0.4
Data expressed as means±s.e.m. FT3, free triiodothyronine; FT4, free thyroxine; TSH thyroid-stimulating hormone. ∗P<. 05, ∗∗P<. 01 versus the control
group; +P<. 05, ++P<. 01 versus the salt group.Journal of Biomedicine and Biotechnology 5
Table 3: Metabolic variables in the experimental groups.
Groups Food intake Water intake Water balance Sodium balance
g/100g·24h mL/100g·24h mL/100g·24h mmol/100g·24h
Control 3.17 ±0.32 7.30 ±0.74 4.71 ±0.59 0.13 ± 0.02
Cloﬁbrate 2.78 ±0.46 6.84 ±1.59 2.56 ±0.68 0.12 ± 0.04
Salt 5.44 ±0.44
∗ 23.55 ±4.48
∗∗ 11.59 ±1.39
∗∗ 5.81 ±0.93
∗∗
Salt+Cloﬁbrate + +3.15 ±0.14 18.04 ±2.48
∗∗ ++2.20 ±0.44
∗ ++0.70 ±0.42
Data expressed as means±s.e.m. ∗P<. 05, ∗∗P<. 01 versus control group; +P<. 05, ++P<. 01 versus. salt group.
Table 4: Urinary variables in experimental groups.
Groups Control Cloﬁbrate Salt Salt+cloﬁbrate
Uv, mL/100g 2.60 ±0.33 3.20 ±0.43 10.01 ±1.00
∗∗ +15.06 ±1.11
∗∗
UNaV, mEq/100g 0.15 ±0.01 0.16 ±0.02 2.76 ±0.42
∗ +7.85 ±1.04
∗
UKV, mEq/100g 0.34 ±0.03 0.35 ±0.03 0.47 ±0.06 +0.77 ±0.08
∗
UCaV, g/100g 0.58 ±0.26 0.73 ±0.16 9.10 ±1.52
∗ +5.85 ±0.15
∗
CrC, mL/min.100g 0.42 ±0.02 0.43 ±0.02 0.52 ±0.03
∗ 0.41 ±0.03
UCrV, mg/100g 3.28 ±0.13 3.15 ±0.18 3.54 ±0.07 3.26 ±0.19
UproteinV, mg/100g 33.51 ±2.25 22.74 ±1.60
∗ 61.20 ±4.76
∗ +43.22 ±2.30
∗
UisoprostaneV, μg/100g 3.85 ±0.68 3.57 ±1.37 .40 ±0.72
∗ 8.22 ±3.18
∗
UNOxV, nM/100g 20.5 ±1.42 2 ±1.54 5 ±1.6
∗∗ 40 ±1.0
∗∗
UETV, pg/100g 2.41 ±1.17 2.19 ±0.48 19.60 ±7.31
∗∗ 16.09 ±3.28
∗∗
UVPV, pg/100g 123.44 ±7.06 121.75 ±8.09 181.04 ±8.36
∗ 172.05 ±10.71
∗
Dataexpressedasmeans±s.e.m.Uv,diuresis;UNaV,natriuresis;UKV,kaliuresis;UcaV,calciuresis;CrC,creatinineclearance;UCrV,totalcreatinineexcretion;
UproteinV, proteinuria; UisoprostaneV, total isoprostanes excretion; UNOxV, total nitrates and nitrites excretion; UETV, total endothelin excretion; UVPV,
total vasopressin excretion. All data are referred to 24h. ∗P<. 05, ∗∗P<. 01 versus control group; +P<. 05, ++P<. 01 versus salt group.
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Figure 2: Tissue levels of free T4 and free T3 (FT4 and FT3) in the experimental groups after ﬁve weeks of treatment. Data are means±SEM.
∗P<. 05 compared with controls. +P<. 05 compared with the salt group.6 Journal of Biomedicine and Biotechnology
with a reduction in plasma FT4 levels and a signiﬁcant
decrease in tissue thyroid hormone levels. These data
contrast with the normal BP and plasma thyroid hormone
levels observed in normal rats treated with cloﬁbrate at the
same dose for three weeks [13]b u ta r ei na g r e e m e n tw i t h
previous reports that ﬁbrates reduce thyroid hormone levels
in several species [10, 27, 28]. The discrepancy with our
previous results suggests that more than three weeks may be
required to observe the antithyroid eﬀects of cloﬁbrate at the
dose used in our study.
Thesaline-treatedratsshowedreducedplasmaandtissue
levels of thyroid hormones, consonant with the decrease
in thyroid hormone levels reported in saline models of
hypertension [29, 30]. This reduced thyroid activity reported
in low-renin hypertension is believed to be mediated by
the action of an unidentiﬁed substance referred to as the
“thyroid-depressing factor” by Threatte et al. [31]. This
substance reduces the uptake and binding of 131I by the
thyroid gland and blocks the 131Iu p t a k es t i m u l a t e db yT S H
[32], and it was found to be increased in the blood of
hypertensive versus normotensive rats [32]. More recently,
several authors reported that low plasma thyroid hormone
levels are the expression of an inﬂammatory state in patients
with chronic renal disease [33] and that plasma and liver
thyroid hormone levels are reduced in uremic rats with
reducedrenalmass[34].Thisthyroidabnormalityisreferred
to as “the euthyroid sick syndrome”, which can also be
produced by elevated saline intake, as indicated by the
present data.
Nitric oxide (NO) plays an important role in renal
function and sodium excretion and regulates the homeo-
static response to an increased sodium intake [16]. Thus,
Shultz and Tolins [16] showed that high salt intake in
rats for 2 weeks resulted in increased serum concentration
and urinary excretion of the NO decomposition products
(NOx) and more recently, salt loading has been used even
as an activator of NO production [15]. In consonance
with this, the present study conﬁrms that increase renal
NOx production is seen following high dietary salt intake.
Cloﬁbrate has also been reported to increase renal NO
production as measured by the urinary excretion of nitrite
[15]. In the present study, however, cloﬁbrate alone did
not increase NOx production, and the increase in nitrite
excretion found with the combination of cloﬁbrate and NaCl
was not greater than that produced by salt alone, while Na
excretion was further increased in comparison to the NaCl
group. The markedly increased natriuresis of the cloﬁbrate-
salt group is consistent with the decreased sodium and water
balance of these rats and can be produced by cloﬁbrate-
stimulated 20-hydroxyeicosatrienoic acid (20-HETE) and
epoxyeicosatrienoic acids (EETs) with natriuretic properties
[35]. This is because ﬁbrates act as inducers of cytochrome
P-450 enzymes [35], which catalyze arachidonic acid for the
formation of 20-HETE and 5- and 6-EET, among others.
Interestingly, the salt+cloﬁbrate-treated rats showed
increased natriuresis and kaliuresis and reduced water and
sodium balance, with higher plasma sodium and lower
potassium levels. All of these observations resemble the
“exaggerated natriuresis” and electrolytic plasma abnor-
malities observed in DOCA-salt treated rats, suggesting
that cloﬁbrate may produce a positive cross-talk pattern
between mineralcorticoid receptors and PPARs at renal
level. Thus, PPARs belong to a large superfamily of nuclear
hormonereceptorsthatincluderetinoicacid(RXR),steroids,
thyroid hormones, and vitamin D receptors [7, 8]. Steroid
and other nuclear hormone receptors can modulate each
other’s transcriptional activities. This cross-talk may result
in inhibition of mineralcorticoid activity, as observed with
thyroid hormones, or in its potentiation, as suggested by the
alterations in the cloﬁbrate salt-treated rats.
Our ﬁnding of increased urinary excretion of iso-
prostanes in the saline-loaded group is in agreement with
reports that a higher saline intake increases NAD(P)H
oxidase activity [17]. Moreover, experimental studies have
demonstrated a PPARα activator-mediated reduction in
oxidative stress [3]. Thus, bezaﬁbrate reduced l-NAME-
induced increases in plasma 8-isoprostane levels, and cloﬁ-
brate diminished the increased NAD(P)H oxidase activity
in DOCA-salt rats [3]. However, cloﬁbrate treatment was
unable to reduce the isoprostane levels in our saline-loaded
rats, suggesting that cloﬁbrate lacks antioxidant properties
under these conditions, probably because the oxidative
stress is lower than observed in L-NAME or DOCA-salt
hypertension.
Our data show that saline-loaded rats have increased
levels of immunoreactive ET and VP. It has been suggested
that ET and VP are stimulated in a compensatory manner
when the renin-angiotensin system is blunted [36]. More-
over, a role has been proposed for both ET and VP in the
development and maintenance of high blood pressure and
renal damage in low-renin models of hypertension [37], and
a positive interaction between them has also been reported
[38].EvidenceoftheinvolvementofrenalETinsaltexcretion
regulation includes ﬁndings of a positive correlation between
changes in natriuresis and urine ET produced by a salt load
[39]. Our data and these observations support participation
of this peptide in the regulation of salt balance. Moreover,
Newaz et al. [3] reported that cloﬁbrate reduced plasma ET
in DOCA/salt hypertensive rats [3]. However, our data show
that PPARα activation was unable to modify the urinary
levels of ET and of VP in saline load hypertension.
In summary, the present study shows that chronic
cloﬁbrate treatment prevents the increased blood pressure of
saline-loaded rats. This eﬀect was associated with a marked
reduction in plasma and tissue thyroid hormone levels
and with a reduced water and sodium balance. However,
cloﬁbrate treatment did not aﬀect variables related to nitric
oxide, oxidative stress, or ET or VP production. Moreover,
cloﬁbrate did not modify the cardiac mass but reduced the
proteinuria of these animals.
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